[The efficacy of pyridonolcarbamate in diabetic angiopathy].
A group of atherosclerotic patients, some of whom were diabetics with clinical and instrumental signs of angiopathy, was treated with pyridinolcarbamate which was found to be elective for diabetic angiopathy. This was seen in the improvement in haemocoagulative alterations (platelet adhesiveness and clumping), that in certain lipidico-plasmatic alterations (normalization or reduction of glycoproteins) and in anatomofunctional modifications at wall level (rheographic modifications and changes in the diffusion curves with Alb labelled with I 131). These improvements were not observed in atherosclerotic subjects.
D001775:Blood Circulation / Q000187:drug effects; D001777:Blood Coagulation / Q000187:drug effects; D002219:Carbamates / Q000627:therapeutic use*; D003925:Diabetic Angiopathies / Q000188:drug therapy*; D006023:Glycoproteins / Q000097:blood; D006801:Humans; D008055:Lipids / Q000097:blood; D010973:Platelet Adhesiveness / Q000187:drug effects; D010974:Platelet Aggregation / Q000187:drug effects; D011727:Pyridinolcarbamate / Q000627:therapeutic use*
D002219:Carbamates; D006023:Glycoproteins; D008055:Lipids; D011727:Pyridinolcarbamate
L'efficacia del piridinolcarbamato nell'angiopatia diabetica